3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase inhibitors have several pleiotropic effects, including anti-inflammatory properties, and are reported to improve endothelial functions. Pathophysiologically, acute lung injury (ALI) is caused by a severe inflammatory response and endothelial dysfunction.
OBJECTIVE:
To investigate the effects of simvastatin (an HMG-CoA reductase inhibitor) on oxidative stress and lung histopathology in 2 murine models of ALI, induced by oleic acid and endotoxin.
METHODS:
The mice were randomly divided into 2 groups: one received 2 mg/kg/d intraperitoneal simvastatin for 15 days. Then the groups were further divided into 3, which received saline, oleic acid, or endotoxin. Four hours after inducing ALI we obtained lung samples for histopathology analysis, myeloperoxidase, glutathione, and malondialdehyde measurement, and blood samples for malondialdehyde measurement.
RESULTS:
Endotoxin and oleic acid lung injury increased tissue myeloperoxidase (P = .009 for both), decreased tissue glutathione (P = .02 and P = .009, respectively), and increased tissue malondialdehyde (P = .009 for both), compared to the control group. Simvastatin decreased myeloperoxidase only in the oleic acid group (P = .01). Simvastatin increased glutathione (P = .005 and P = .003, respectively) and lowered malondialdehyde in both the endotoxin and oleic acid groups (P = .003 for both). Histopathology revealed that simvastatin protected the lung tissue in both ALI models, but the protection was greater in the endotoxin group.
CONCLUSIONS:
Pretreatment with simvastatin decreased the severity of ALI in oleic acid and endotoxin ALI models, by decreasing inflammation and oxidative stress.
Brun-BuissonC, MinelliC, BertoliniG, BrazziL, PimentelJ, LewandowskiK, et al. for the ALIVE Study Group. Epidemiology and outcome of acute lung injury in European intensive care units. Results from the ALIVE study. Intensive Care Med, 2004; 30(1):51–61.
2.
ZhangH, SlutskyAS, VincentJL. Oxygen free radicals in ARDS, septic shock and organ dysfunction. Intensive Care Med, 2000; 26(4):474–476.
3.
The Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med, 2000; 342(18):1301–1308.
4.
CalfeeCS, MatthayMA. Nonventilatory treatments for acute lung injury and ARDS. Chest, 2007; 131(3):913–920.
5.
RoccoPR, ZinWA. Pulmonary and extrapulmonary acute respiratory distress syndrome: are they different?. Curr Opin Crit Care, 2005; 11(1):10–17.
6.
CalabroP, YehET. The pleiotropic effects of statins. Curr Opin Cardiol, 2005; 20(6):541–546.
7.
Blanco-ColioLM, TunonJ, Martin-VenturaJL, EgidoJ. Anti-inflammatory and immunomodulatory effects of statins. Kidney Int, 2003; 63(1):12–23.
8.
TesfamariamB. The effects of HMG-CoA reductase inhibitors on endothelial function. Am J Cardiovasc Drugs, 2006; 6(2):115–120.
9.
KrugerP, FitzsimmonsK, CookD, JonesM, NimmoG. Statin therapy is associated with fewer deaths in patients with bacteraemia. Intensive Care Med, 2006; 32(1):75–79.
10.
AlmogY, SheferA, NovackV, MaimonN, BarskiL, EizingerM, et al. Prior statin therapy is associated with a decreased rate of severe sepsis. Circulation, 2004; 110(7):880–885.
11.
LiappisAP, KanVL, RochesterCG, SimonGL. The effect of statins on mortality in patients with bacteremia. Clin Infect Dis, 2001; 33(8):1352–1357.
12.
FedsonDS. Pandemic influenza: a potential role for statins in treatment and prophylaxis. Clin Infect Dis, 2006; 43(2):199–205.
13.
Irish Critical Care Trials Group. Acute lung injury and the acute respiratory distress syndrome in Ireland: a prospective audit of epidemiology and management. Crit Care, 2008; 12(1):R30.
14.
MajumdarSR, McAlisterFA, EurichDT, PadwalRS, MarrieTJ. Statins and outcomes in patients admitted to hospital with community acquired pneumonia: population based prospective cohort study. BMJ, 2006; 333(7576):999.
15.
KorDJ, IscimenR, YilmazM, BrownMJ, BrownDR, GajicO. Statin administration did not influence the progression of lung injury or associated organ failures in a cohort of patients with acute lung injury. Intensive Care Med, 2009; 35(6):1039–1046.
16.
YamadaM, HuangZ, DalkaraT, EndresM, LaufsU, WaeberC, et al. Endothelial nitric oxide synthase-dependent cerebral blood flow augmentation by L-arginine after chronic statin treatment. J Cereb Blood Flow Metab, 2000; 20(4):709–717.
17.
BaykalA, KavukluB, IskitAB, GucMO, HascelikG, SayekI. Experimental study of the effect of nitric oxide inhibition on mesenteric blood flow and interleukin-10 levels with a lipopolysaccharide challenge. World J Surg, 2000; 24(9):1116–1120.
McGuiganRM, MullenixP, NorlundLL, WardD, WaltsM, AzarowK. Acute lung injury using oleic acid in the laboratory rat: establishment of a working model and evidence against free radicals in the acute phase. Curr Surg, 2003; 60(4):412–417.
20.
SchulzR, NavaE, MoncadaS. Induction and potential biological relevance of a Ca2+-independent nitric oxide synthase in the myocardium. Br J Pharmacol, 1992; 105(3):575–580.
21.
AkbiyikF, DemirpenceE, KuzuMA, KilincK. In vitro and in vivo inhibition of myeloperoxidase with 5-fluorouracil. Eur J Clin Pharmacol, 2001; 57(9):631–636.
22.
TietzeF. Enzymatic method of quantitative determination of nanogram amounts of total and oxidized glutathion: applications to mammalian blood and other tissues. Anal Biochem, 1969; 27(3):502–522.
23.
MiharaM, UchiyamaM. Determination of malonaldehyde precursor in tissues by thiobarbituric acid test. Anal Biochem, 1978; 86(1):271–278.
24.
LowryOH, RosebroughNJ, FarrAL, RandallRJ. Protein measurement with the Folin phenol reagent. J Biol Chem, 1951; 193(1):265–275.
25.
PiratA, ZeynelogluP, AldemirD, YucelM, OzenO, CandanS, ArslanG. Pretreatment with simvastatin reduces lung injury related to intestinal ischemia-reperfusion in rats. Anesth Analg, 2006; 102(1):225–232.
26.
RottaAT, VianaME, WiryawanB, SargentelliGA, DowhyMS, ZinWA, FuhrmanBP. Combining lung-protective strategies in experimental acute lung injury: the impact of high-frequency partial liquid ventilation. Pediatr Crit Care Med, 2006; 7(6):562–570.
27.
ChelloM, PattiG, CanduraD, MastrobuoniS, Di SciascioG, AgroF, et al. Effects of atorvastatin on systemic inflammatory response after coronary bypass surgery. Crit Care Med, 2006; 34(3):660–667.
28.
HackamDG, MamdaniM, LiP, RedelmeierDA. Statins and sepsis in patients with cardiovascular disease: a population-based cohort analysis. Lancet, 2006; 367(9508):413–418.
29.
WilliamsJP, HernadyE, JohnstonCJ, ReedCM, FentonB, OkunieffP, FinkelsteinJN. Effect of administration of lovastatin on the development of late pulmonary effects after whole-lung irradiation in a murine model. Radiat Res, 2004; 161(5):560–567.
30.
OzansoyG, GuvenC, CeylanA, CanB, AktanF, OzE, GonulB. Effects of simvastatin treatment on oxidant/antioxidant state and ultrastructure of streptozotocin-diabetic rat lung. Cell Biochem Funct, 2005; 23(6):421–426.
YaoHW, MaoLG, ZhuJP. Protective effects of pravastatin in murine lipopolysaccharide-induced acute lung injury. Clin Exp Pharmacol Physiol, 2006; 33(9):793–797.
33.
LiX, KlintmanD, Weitz-SchmidtG, SchrammR, ThorlaciusH. Lymphocyte function antigen-1 mediates leukocyte adhesion and subsequent liver damage in endotoxemic mice. Br J Pharmacol, 2004; 141(4):709–716.
34.
ShyamsundarM, CraigT, O'KaneC, McAuleyD. Comment on “Statin administration did not influence the progression of lung injury or associated organ failures in a cohort of patients with acute lung injury”. Intensive Care Med, 2009; 35(8):1494–1495.
35.
JacobsonJR, BarnardJW, GrigoryevDN, MaSF, TuderRM, GarciaJG. Simvastatin attenuates vascular leak and inflammation in murine inflammatory lung injury. Am J Physiol, 2005; 288(6):L1026–1032.
36.
RemickDG, WardPA. Evaluation of endotoxin models for the study of sepsis. Shock, 2005; 24(Suppl 1):7–11.
37.
SchusterDP. ARDS. clinical lessons from the oleic acid model of acute lung injury. Am J Respir Crit Care Med, 1994; 149(1):245–260.
38.
RojasM, WoodsCR, MoraAL, XuJ, BrighamKL. Endotoxin-induced lung injury in mice: structural, functional, and biochemical responses. Am J Physiol, 2005; 288(2):L333–L341.
39.
RosenthalC, CaroniaC, QuinnC, LugoN, SagyM. A comparison among animal models of acute lung injury. Crit Care Med, 1998; 26(5):912–916.
40.
ClaessonJ, LehtipaloS, BergstrandU, ArnerlovC, RocksenD, HultinM, WinsoO. Intestinal circulation, oxygenation and metabolism is not affected by oleic acid lung injury. Clin Physiol Funct Imaging, 2005; 25(6):357–363.
41.
AyanE, Bayram KaplanM, KokselO, TamerL, KarabacakT, AyazL, OzdulgerA. Efficiency of lornoxicam in lung and trachea injury caused by peroxynitrite. Pulm Pharmacol Ther, 2008; 21(1):201–207.
42.
AytacogluBN, CalikogluM, TamerL, CoskunB, SucuN, KoseN, et al. Alcohol-induced lung damage and increased oxidative stress. Respiration, 2006; 73(1):100–104.
43.
IidaK, GolandS, AkimaT, LuoH, BirnbaumY, SiegelRJ. Effect of a single 20-mg tablet of Atorvastatin on brachial artery blood flow in normolipidemic male smokers versus nonsmokers. Am J Cardiol, 2007; 100(5):881–884.
44.
MerxMW, LiehnEA, GrafJ, van de SandtA, SchaltenbrandM, SchraderJ, HanrathP. Statin treatment after onset of sepsis in a murine model improves survival. Circulation, 2005; 112(1):117–124.
45.
McClintockDE, WareLB, EisnerMD, WickershamN, ThompsonBT, MatthayMA. National Heart, Lung, and Blood Institute ARDS Network. Higher urine nitric oxide is associated with improved outcomes in patients with acute lung injury. Am J Respir Crit Care Med, 2007; 175(3):256–262.
46.
LopezA, LorenteJA, SteingrubJ, BakkerJ, McLuckieA, WillattsS, et al. Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit Care Med, 2004; 32(1):21–30.
47.
NeumannP, GertzbergN, JohnsonA. TNF-alpha induces a decrease in eNOS promoter activity. Am J Physiol, 2004; 286(2):L452–L459.
